Akman M N, Loubser P G, Donovan W H, O'Neill M E, Rossi C D
Department of Physical Medicine and Rehabilitation, Inonu University Medical School, Malatya, Turkey.
Paraplegia. 1993 Aug;31(8):516-20. doi: 10.1038/sc.1993.84.
Concern over the development of tolerance in patients on continuous intrathecal baclofen therapy has arisen as this new form of treatment for spasticity has gained wider use. We have studied time-dose relationships in 18 spinal cord injured patients who have undergone intrathecal baclofen infusion pump implantation since February 1988 in our facility. Our data show that there was a significant increase in baclofen dosage needed to control spasticity during the first 12 months post implantation. After 12 months, however, no significant changes in dosage requirement was detected. In addition, there was no significant difference between completely and incompletely spinal cord injured patients with regard to both the initial dose and the tolerance trend.
随着鞘内持续注射巴氯芬这种治疗痉挛的新方法得到更广泛应用，人们开始关注接受该治疗的患者产生耐受性的问题。自1988年2月起，我们对在本机构接受鞘内巴氯芬输注泵植入手术的18例脊髓损伤患者的时间-剂量关系进行了研究。我们的数据显示，植入后的前12个月，控制痉挛所需的巴氯芬剂量显著增加。然而，12个月后，未检测到剂量需求有显著变化。此外，完全性和不完全性脊髓损伤患者在初始剂量和耐受性趋势方面均无显著差异。
